Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Glaxo to Acquire Red-Wine Pill Maker Sirtris - Nutraceuticals World

What are you searching for?

Sign in
Market Updates

Glaxo to Acquire Red-Wine Pill Maker Sirtris

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

According to the April 22nd edition of the Wall Street Journal, GlaxoSmithKline will acquire Sirtris Pharmaceuticals, a Massachusetts company that’s developing a drug based on resveratrol, a chemical found in red wine that is thought to fight some effects of aging.

Glaxo said in a news release that the $720 million deal will help it get involved with sirtuins, a recently-discovered class of enzymes believed to have a role in the aging process. The WSJ article went on to say that Sirtris’ red-wine drug, which targets the sirtuin 1 enzyme, was well-tolerated and safe for patients in an early study in diabetics.

It’s still early to tell whether the drug, code named SRT501, will work out. In the meantime, WSJ claims Sirtris has also been working on some new compounds that it says mimic the effects of resveratrol but with much more potency. Glaxo said targeting the sirtuin family could help it address diseases associated with metabolism and aging such as diabetes, muscle wasting and neurodegeneration.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics